Compare ArcelorMittal SA (MT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Novo Nordisk A/S — how do they compare? ArcelorMittal SA trades at $64.3 (market cap $45.70B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.6× ArcelorMittal SA's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Novo Nordisk A/S for 116 Days on average.
| MT | NVO | |
|---|---|---|
Market Cap | $45.70B | $165.31B |
Volume | 1,964,621 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $63.98 |
52-Week Low | $36.91 | $35.29 |
Typical Hold Time | 36 Days | 116 Days |
Enterprise Value | $55.27B | $179.56B |
Dividend Yield | 0.98% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $64.11, up 2.87% with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported Q2 2026 earnings miss but maintains strong cash flow and operational momentum. Recent news highlights challenges from Ukraine plant disruptions with a $1 billion impairment charge, though strategic expansions and Microsoft partnership provide growth catalysts. Valuation remains attractive with P/S of 0.75 and P/B of 0.84.
Outlook remains cautiously optimistic with analyst consensus price target of $74.33 offering 16% upside. Key risks include geopolitical exposure in Ukraine, volatile steel demand, and elevated capital expenditures. The stock presents value opportunity given discounted valuations against sector peers, supported by improving European order books and shareholder returns through dividends.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
